Evidence that adequacy of dialysis modulates uremic anemia

Nephron

Volumn 88, Issue 1, 2001, Pages 1-5

  Ifudu, Onyekachi ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL TRIAL; DIALYSIS; HEMATOCRIT; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; IRON KINETICS; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; UREMIA;

ANEMIA; ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; UREMIA;

EID: 0035018755     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045951     Document Type: Review

References (69)

1. Xia H, Ebben J, Ma JZ, et al: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-1316.
2. Ma JZ, Ebben J, Xia H, et al: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
3. Health Care Financing Administration. 1998 Annual Report, End-Stage Renal Disease Care Indicators Project. Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, Baltimore, Dec 1998.
4. Cotter JC, Thamer M, Kimmel PL, et al: Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996. Kidney Int 1998;54:2129-2139.
5. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
6. Lundin AP: Quality of life: Subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 1989;9:22-29.
7. Braumann KM, Nonnast-Daniel B, Boning D, et al: Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991;58:129-134.
8. Madore F, Lowrie E, Brugnara C, et al: Anaemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-1929.
9. Ifudu O, Matthew JJ, Mayers JD, et al: Severity of acquired immunodeficiency syndrome and the response to erythropoietin in uremia. Am J Kidney Dis 1997;30:28-35.
10. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334:420-425.
11. Ifudu O, Waring S, Rasmussen G, Friedman EA: Dialysis adequacy explains regional and hemodialysis facility differences in hematocrit in patients with end-stage renal disease receiving erythropoietin (abstract). J Am Soc Nephrol 1999;10:284A.
12. National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 1997;30:S192-S237.
13. Cohen D, Raja RM: Erythropoietin requirements remain high in erythropoietin-resistant patients after iron repletion. ASAIO J 1998;44: M596-M597.
14. Danielson BG, Salmonson T, Derendorf H, et al: Pharmacokinetics of iron (III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615-621.
15. Reece WD, Brackelsberg PO, Hotchkiss DK: Erythrocyte changes, serum iron concentration and performance following iron injection in neonatal beef calves. J Anim Sci 1985;61: 1387-1394.
16. Henderson PA, Hillman RS: Characteristics of iron dextran utilization in man. Blood 1969;34: 357-375.
17. 59Fe-dextran complex in human subjects. Br Med J 1957;8:1074-1077.
18. Douvas GS, May MH, Pearson JR, et al: Hypertriglyceridemia, very low density lipoprotein, and iron enhance Mycobacterium avium replication in human macrophages. J Infect Dis 1994;170:1248-1255.
19. Barry DM, Reeve AW: Increased incidence of gram-negative neonatal sepsis with intramuscular iron administration. Pediatrics 1977;60: 908-912.
20. Webster MH, Waitkins SA, Stott A: Impaired bacteriological responses in babies after maternal iron dextran infusion. J Clin Pathol 1981; 34:651-654.
21. Scheuermann EH, Belwe V, Blaser C, et al: Parenteral iron causes increased lipid peroxidation in hemodialysis patients (abstract). J Am Soc Nephrol 1997;8:251A.
22. Collins A, Ebben J, Ma J: Frequent intravenous iron dosing is associated with higher infectious deaths (abstract). J Am Soc Nephrol 1997;8: 190A.
23. Boelaert JR, Daneels RF, Schurgers ML, et al: Iron overload in hemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 1990;5:130-134.
24. Patruta SI, Edlinger R, Sunder-Plassmann G, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-663.
25. Hoen B, Kessler M, Hestin D, et al: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Tansplant 1995;10: 377-381.
26. Collins A, Ebben J, Ma J, et al: Intravenous iron-dosing patterns and mortality (abstract). J Am Soc Nephrol 1998;9:205A.
27. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993;3:1541-1554.
28. Ifudu O, Friedman EA: Economic implications of inadequate response to erythropoietin in patients with end-stage renal disease. Dial Transplant 1997;26:664-669.
29. Wallner SF, Vautrin RM: Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 1981;97:170-178.
30. Markson JL, Rennie JB: The anemia of chronic renal insufficiency. Scot Med J 1956;1:320-322.
31. Radtke HW, Rege AB, LaMarche MB, Bartos D, Campbell RA, Fisher JW: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981;67:1623-1629.
32. Essers U, Muller W, Heintz R: Effect of erythropoietin in normal men and in patients with renal insufficiency. Proc Eur Dial Transplant Assoc 1974;11:398-402.
33. Saito A, Suzuki I, Chung TG, et al: Separation of an inhibitor of erythropoiesis in 'middle molecules' from hemodialysate from patients with chronic renal failure. Clin Chem 1986;32: 1938-1941.
34. Ortega JA, Malekzadeh MH, Dukes PP, Ma A, Pennisi AV, Fine RN, Shore NA: Exceptionally high serum erythropoietin activity in an anephric patient with severe anemia. Am J Hematol 1977;2:299-306.
35. Kushner D, Beckman B, Nguyen L, et al: Polyamines in the anemia of end-stage renal disease. Kidney Int 1991;39:725-732.
36. Delwiche F, Segal GM, Eschbach JW, et al: Hematopoietic inhibitors in chronic renal failure: Lack of in vitro specificity. Kidney Int 1986;29:641-648.
37. McGonigle RJS, Husserl F, Wallin JD, Fisher JW: Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984;25:430-436.
38. Zappacosta AR, Caro J, Erlev A: Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am J Med 1982;72:53-57.
39. Urabe A, Chiba S, Kosaka K, et al: Response of uremic bone marrow cells to erythropoietin in vitro. Scand J Haematol 1976;17:335-340.
40. Sun CH, Ward HJ, Paul WL, et al: Serum erythropoietin levels after renal transplantation. N Engl J Med 1989;321:151-157.
41. Santiago GC, Rao TKS, Laird NM: Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study. Kidney Int 1983;23:S95-S100.
42. Geerlings W, Morris RW, Brunner FP, et al: Factors influencing anemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplant 1993;8:585-589.
43. Koch KM, Patyna WD, Shaldon S, Werner E: Anemia of the regular hemodialysis patient and its treatment. Nephron 1974;12:405-419.
44. Stegeman CA, Kloppenburg WD, Huisman RM, de Jong PE: The erythropoietin dose correlates with dialysis adequacy in patients on chronic hemodialysis (abstract). J Am Soc Nephrol 1995;6:563.
45. Movilli E, Cancarini GC, Verzeletti F, et al: Effect of adequacy of dialysis on recombinant erythropoietin doses in hemodialysis patients (abstract). J Am Soc Nephrol 1999;10:335A.
46. Borawski J, Pawlak K, Mysliwiec M: Variables affecting hemoglobin level in hemodialysis patients (abstract). Nephrol Dial Transplant 1999;13:A252.
47. Yang CS, Chen SW, Chiang CH, et al: Effects of increasing dialysis dose on serum albumin and mortality in hemodialysis patients. Am J Kidney Dis 1996;27:380-386.
48. Feest T, Ansell D, Taylor H, et al: Influences on achievement of hemoglobin equal to or greater than 10g/dl without erythropoietin in dialysis patients - UK Data (abstract). Nephrol Dial Transplant 1999;14:A255.
49. Scaini P, Sandrini M, Zani R, et al: Adequacy reduces erythropoietin dose in peritoneal dialysis patients (abstract). Nephrol Dial Transplant 1999;14:A258.
50. Opatrná S, Opatrný K Jr, Cejková P, et al: Relationship between anemia and adequacy of continuous ambulatory peritoneal dialysis. Nephron 1997;77:359-360.
51. Tzamaloukas AH, Murata GH, Sena P: When do plasma levels of azotemic indices indicate inadequacy of peritoneal dialysis? Nephron 1994;67:495-496.
52. Muirhead N, Cattran DC, Zaltzman J, et al: Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 1994;5:1216-1222.
53. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF Jr, for the ESRD Core Indicators Work Group: Anemia management of adult hemodialysis patients in the US: Results from the 1997 ESRD core indicators project. Kidney Int 2000;57:578-589.
54. Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D: Radioimmunoassay of erythropoietin in chronic uremic or anephric patients. Scand J Haematol 1986;37:390-394.
55. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N: Erythropoietin production in patients with chronic renal failure. Ren Fail 1994;16:645-651.
56. Ifudu O, Friedman EA: Effect of increased hemodialysis dose on endogenous erythropoietin production in end-stage renal disease. Nephron 1998;79:50-54.
57. Morris K, Coulthard M: End-stage kidneys are capable of increased erythropoietin production. Pediatr Nephrol 1993;7:273-275.
58. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W: Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int 1987;31:1205-1209.
59. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 1985;39:26-29.
60. Ifudu O, Fowler A: Hepatitis B virus surface antigenemia and the response to erythropoietin in patients with end-stage renal disease (abstract). ASAIO J 1997;43:76.
61. Chan N, Barton CH, Mirahmadi MS, et al: Erythropoiesis associated with viral hepatitis in end-stage renal disease. Am J Med Sci 1984; 287:56-58.
62. Petronis KR, Carroll CE, Held PJ, Port FK: Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA 1994;271:1760-1763.
63. Eschbach JW, Funk D, Adamson J, Kuhn J, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967;276:653-658.
64. Shaw AB: Hemolysis in chronic renal failure. Br Med J 1967;2:213-216.
65. Hartitzsch BV, Carr D, Kjellstrand CM, Kerr DNS: Normal red cell survival in well-dialyzed patients. Trans ASAIO 1973;19:471-474.
66. Najean Y, Moynot A, Deschryver F, Zins B, Naret C, Jacquot C, Drueke T: Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin. Nephrol Dial Transplant 1989;4:350-355.
67. Taniguchi S, Shibuya T, Harada M, Niho Y: Prostaglandin-mediated suppression of in vitro growth of erythroid progenitor cells. Kidney Int 1989;36:712-718.
68. Jones AL, Millar JL: Growth factors in haemopoiesis. Baillières Clin Haematol 1989;2:83-111.
69. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F, for the Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000;11:335-342.